Compare Check Point Software Technologies Ltd (CHKP) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Check Point Software Technologies Ltd vs Crispr Therapeutics AG — how do they compare? Check Point Software Technologies Ltd trades at $128.76 (market cap $13.18B), while Crispr Therapeutics AG trades at $54.19 (market cap $5.23B). The key difference: Check Point Software Technologies Ltd is far larger — about 2.5× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| CHKP | CRSP | |
|---|---|---|
Market Cap | $13.18B | $5.23B |
Sector | Technology | Health |
52-Week High | $206.91 | $76.78 |
52-Week Low | $112.47 | $44.34 |
Enterprise Value | $12.88B | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Check Point Software Technologies (CHKP) trades at $128.21, down 2.23% on the day, reflecting recent bearish pressure. The stock shows strong profitability with a net margin of 37.93% and has beaten earnings estimates for three consecutive quarters. Technical indicators signal a bearish trend, with the price near support at $128. Recent news highlights AI security growth potential and insider selling activity.
The outlook is mixed: valuation appears attractive with a P/E of 13.24, but growth challenges and margin pressures pose risks. Analyst consensus leans neutral with a $146.92 price target, suggesting cautious optimism for recovery driven by AI security demand, though competitive and execution risks remain.
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
